J Cancer 2016; 7(2):192-199. doi:10.7150/jca.13414
Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis
1. National Engineering Laboratory for Rice and Byproduct Deep Processing, Central South University of Forestry and Technology, Changsha, Hunan 410004, China;
2. Medical College, Hunan Normal University, Changsha, Hunan 410013, China;
3. College of Biology, Hunan University, Changsha, Hunan 410082, China.
4. Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
* These authors contributed equally to this work.
Despite the tremendous improvement in cancer therapeutics, treatment of late-stage breast cancer remains a challenge for both basic scientists and clinicians. Lovastatin, a natural product derived from Aspergillus terreus or Monascus ruber, has been widely used as cholesterol-lowing drug in the clinic. It also has anti-cancer properties through poorly defined molecular mechanisms. In the present study, we employed a novel antibody microarray technology to investigate the molecular mechanisms through which lovastatin inhibits breast cancer. We found that lovastatin up-regulated 17 proteins and down-regulated 20 proteins in MDA-MB-231 breast cancer cells. These included proteins that modulate apoptosis, cell proliferation, differentiation, signal transduction, epithelial-to-mesenchymal transition and tumor metastasis. Modulation of these pathways may mediate, in part, the inhibitory activity of lovastatin on breast cancer.
Keywords: Natural products, Lovastatin, Breast cancer, Antibody microarray, Hypoxia
Yang T, Yao H, He G, Song L, Liu N, Wang Y, Yang Y, Keller ET, Deng X. Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. J Cancer 2016; 7(2):192-199. doi:10.7150/jca.13414. Available from http://www.jcancer.org/v07p0192.htm